Recent work further implicates BHLHE40-driven glycolytic reprogramming in polarizing neutrophils toward a pro-tumor phenotype (48), highlighting metabolic targeting as a therapeutic strategy. This evidence concerns the gene BHLHE40 and neoplasm.